The Head of the Association of the Russian pharmaceutical manufacturers, Viktor Dmitriev, speaking at the meeting of the Integration Council of the Russian Union of Industrialists and Entrepreneurs, claimed that “The documents have been signed, but so far the union pharmaceutical market works only on paper. Unfortunately, in the nearest future we do not expect a “starting shot,” although we extremely hope for it.”
However, this hope seems rather illusive, as the pharmaceutical companies are afraid of competitive environment openness, and therefore they are not in hurry up the implementation of the ideas of the union EurAsEC market. Also, among the main reasons for the delay in the launch of the program by Russian pharmaceuticals are the interdepartmental disagreements within the Russian Federation and the uncertainty of the consequences for business. The Ministry of Industry and Trade is responsible for the control of production, the Ministry of Health is involved in the registration of medicines, Roszdravnadzor monitors the quality control of the drugs, and FAS is responsible for maintaining the competitive environment. These four agencies often cannot come to a single decision as soon as possible.
Explicit problems are also present in the pharmaceutical industry. In Russia, effective production chains should be created. However, as Dmitriev stated, “… this market is not interesting for machine tool builders”, so today the Russian pharma market is completely dependent on imported equipment.
It will take several years to improve the situation and eliminate these difficulties, which means that the union EurAsEC market will really start functioning in the distant future only.